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In Brief
Neuroligins and neurexins form transsynaptic bridges that promote synapse development; a third family of synaptic organizers, MDGAs, regulates these bridges. Gangwar et al. demonstrate the molecular mechanism underlying the regulatory action of MDGAs.
INTRODUCTION
Synaptic adhesion and organizing molecules, also known as ''synaptic organizers,'' play an essential role in the development of synapses, the contact and communication points between neurons. The synaptic organizers, neuroligins and neurexins, extend their extracellular domains out into the synaptic cleft, where they form trans-synaptic bridges with each other (reviewed in Reissner et al., 2013) . Interaction of neuroligins with neurexins promotes the development of synapses and normal synaptic transmission (Reissner et al., 2013) . Recently, it was discovered that a third family of cell-surface molecules, the MDGAs (MAM domain-containing glycosylphosphatidylinositol anchors), regulates the trans-synaptic interaction between neuroligins and neurexins (Connor et al., 2016; Lee et al., 2013; Pettem et al., 2013) , though the underlying molecular mechanism is unknown.
Neuroligins and neurexins form large families of adhesion molecules and their members are implicated in neuropsychiatric disease. In humans, five neuroligin genes (NLGN1, NLGN2, NLGN3, NLGN4X, and NLGN4Y) and three neurexin genes (NRXN1, NRXN2, and NRXN3) exist (Bemben et al., 2015; Reissner et al., 2013) . Both neuroligins and neurexins are diversified through alternative splicing of mRNA transcripts; in particular, NLGN2 can accommodate a splice insert at site A, while NLGN1 can carry a splice insert at site A as well as a second splice insert at site B (Boucard et al., 2005; Chih et al., 2006; Schreiner et al., 2014 Schreiner et al., , 2015 Treutlein et al., 2014) . NLGN2 localizes specifically to inhibitory synapses, while NLGN1 (NLGN1 + site B) is predominant at excitatory synapses (Chubykin et al., 2007; Futai et al., 2013; Gibson et al., 2009; Levinson et al., 2005; Varoqueaux et al., 2004) . Splice inserts can regulate the affinities of neuroligins and neurexins for their protein partners (reviewed in Reissner et al., 2013) . Strikingly, lesions in both neurexins and neuroligins are implicated in autism spectrum disorder and schizophrenia (Bé na et al., 2013; Bourgeron, 2016; Reissner et al., 2013; Sun et al., 2011) . Because these molecules impact the development of excitatory synapses and inhibitory synapses differentially, malfunction of select neuroligin and neurexin members is thought to lead to an imbalance in excitation versus inhibition, disrupting neural circuits critical to cognition and behavior (Lee et al., 2017) .
MDGAs (MDGA1 and MDGA2) regulate the interaction between neuroligins and neurexins. MDGAs are also implicated in autism spectrum disorder and schizophrenia (Bucan et al., 2009; K€ ahler et al., 2008; Li et al., 2011) . During neural development, MDGA1 controls the radial migration of cortical neurons (Ishikawa et al., 2011; Takeuchi and O'Leary, 2006) , but it continues to be expressed postnatally at high levels as well (Lee et al., 2013) . MDGAs are composed of six immunoglobulin (Ig) domains, a fibronectin type III (FNIII) domain and an MAM (meprin, A5 protein, PTPm) domain, and they are tethered putatively to the post-synaptic membrane by a glycosylphosphatidylinositol (GPI) anchor (Litwack et al., 2004) . MDGA1 binds specifically to NLGN2 with nanomolar affinity, but not to NLGN1 or NLGN3, forming a side-by-side (in cis) complex involving the extracellular domains; in contrast, MDGA2 prefers to interact with NLGN1 (Connor et al., 2016; Lee et al., 2013; Pettem et al., 2013) . The interaction of MDGA1 with NLGN2 blocks the ability of NLGN2 to form a trans-synaptic bridge with neurexins, thus downregulating the ability of NLGN2 to promote inhibitory synapse development; on the other hand, there is consensus that MDGA2 downregulates excitatory synapse formation (Connor et al., 2016; Lee et al., 2013; Loh et al., 2016; Pettem et al., 2013) .
The three-dimensional structure of MDGA1 and the molecular mechanism by which it binds NLGN2 are unknown. Previous studies have revealed that the first three Ig domains of MDGA1 are sufficient to bind NLGN2 (Lee et al., 2013; Pettem et al., 2013) . But it is not clear how MDGA1 regulates the interaction of NLGN2 with neurexins. NLGN2 forms an ellipsoidal dimer in the synaptic cleft; each monomer is composed of a globular cholinesterase domain and a helical dimerization domain that contributes two helices to the dimerization interface . A post-synaptically tethered neuroligin dimer forms a neurexin:neuroligin trans-synaptic bridge by recruiting to each of its lateral sides a pre-synaptically tethered neurexin via a select LNS domain (Araç et al., 2007; Chen et al., 2008; Fabrichny et al., 2007; Leone et al., 2010) . To understand how MDGA1 regulates the NLGN2:neurexin trans-synaptic bridge, we embarked on molecular and structural studies of these proteins. We show that MDGA1 Ig1-Ig2 is sufficient to bind NLGN2 with nanomolar affinity and determine the crystal structures of MDGA1 Ig1-Ig2 (2.7 Å ) and the complex between NLGN2 and MDGA1 Ig1-Ig2 (4.1 Å ). We elucidate the molecular mechanism by which the synaptic organizer MDGA1 can downregulate inhibitory synapse development and reveal the first structure of the NLGN2 ectodomain in complex with a protein partner.
RESULTS
We overexpressed the extracellular domains of MDGA1 and NLGN2 ( Figure 1A ) and obtained pure, monodisperse preparations ( Figures 1B, 1C , and S1). We also generated a panel of MDGA1 fragments in order to map the minimal domains required to bind NLGN2 ( Figure 1D ). To measure interaction between MDGA1 and NLGN2 in solution, we designed a fluorescence polarization (FP)-based assay and revealed that full-length ectodomains of MDGA1 and NLGN2 bind each other with a K D of 48 ± 13 nM ( Figures 1E and 1F ). MDGA1 Ig1-Ig3 bound NLGN2, in agreement with Pettem et al. (2013) and Lee et al. (2013) ; however, the shorter Ig1-Ig2 construct was sufficient to bind NLGN2 with a K D of 21 ± 16 nM ( Figures 1E and 1F ). Ig2-Ig3 did not bind NLGN2 significantly, nor did the isolated domains, Ig1 and Ig3; unfortunately, we could not test Ig2 because we were unable to overexpress it. Taken together, our data suggest that the MDGA1 Ig1-Ig2 array is sufficient and required to bind NLGN2.
To gain insight into the architecture of the MDGA1 Ig1-Ig2 tandem, we determined its crystal structure to a resolution of 2.7 Å (Figures 2A and 2B ; Table 1 ). Ig1 adopts an eight-stranded b sandwich composed of a three-stranded b sheet (b1, b4, and b6) and a five-stranded b sheet (b2, b3, b5, b7, and b8). With the exception of strands b2 and b3 and loop b5-b6, the core of Ig1 is reminiscent of domains found in perlecan, the FGF receptor 2, and synCAM. Ig2 adopts a classical C-type seven-stranded immunoglobulin fold composed of a three-stranded b sheet (b11, b14, and b15) and a four-stranded b sheet (b9, b10, b12, and b13), like domains found in DSCAM1 and NCAM2. The MDGA1 Ig1-Ig2 tandem forms a rigid, rod-shaped molecule, stabilized by two intradomain and one interdomain disulfide bonds. In both Ig1 and Ig2, the middle strand in the threestranded b sheet is disulfide bonded to an inner strand of the opposing b sheet; i.e., Cys 60 and Cys 108 link strand b4 and strand b7 together in Ig1, while Cys 157 and Cys 214 link strand b10 and strand b14 in Ig2. This feature is known to contribute to the structural stability of Ig-like domains (Hagihara and Saerens, 2014) . Several striking structural features stabilize the interface between Ig1 and Ig2 ( Figure 2C significant surface they bury ($715 Å 2 ), and conservation of this interdomain disulfide bond in the MDGA family ( Figure S2 ) further supports that these two domains are locked in place with respect to each other. To understand how MDGA1 interacts with NLGN2, we determined the crystal structure of MDGA1 Ig1-Ig2 in complex with NLGN2 to a resolution of 4.1 Å ( Table 1 ). The crystals exhibit the symmetry of space group P1 and contain three complexes in the asymmetric unit ($4,300 residues in total). Each complex consists of an NLGN2 dimer with two MDGA1 Ig1-Ig2 tandems bound. The molecular packing permitted us to exploit 6-fold non-crystallographic symmetry restraints, enabling stable refinement of the atomic model despite the relatively low resolution of the diffraction data and the massive protein content (580 kDa; 33,540 atoms). The structure of the complex reveals that MDGA1 Ig1 and Ig2 both bind NLGN2 and that the tandem straddles the NLGN2 dimer with each Ig domain interacting with a different NLGN2 monomer ( Figures 3A and 3B ). Molecular interactions underlying the binding mechanism are shown in Figures 3C and 3D (see also Figure S3 ). MDGA1 Ig1 docks on NLGN2 using strands b3, b5, b7, and b8; in turn, NLGN2 binds MDGA1 Ig1 via the long loop a10-a11, helix a11, and several residues from loop a4-a5 and loop a6-a7. In total, 16 residues of MDGA1 Ig1 and 21 residues of NLGN2 form interactions closer than 5 Å . To validate the interaction between MDGA1 and NLGN2 observed in the crystal structure, we replaced key residues found at the interface with alanine residues or oppositely charged residues and tested their binding ( Figures 3E-3G ). Mutations at the interface between Ig1 and NLGN2 (NL2-Mut1, NL2-Mut4, MDGA1 C8_Mut2, and MDGA1 C8_Mut5) severely disrupted binding between the MDGA1 Ig1-Ig2 tandem and NLGN2 in solution, e.g., mutations on the NLGN2 surface decreased the binding affinity $ten times or more. Likewise, mutations at the interface between Ig2 and NLGN2 (MDGA1 C8_Mut3) disrupted binding of the complex, as did more dramatic combinations of mutations that targeted both Ig1 and Ig2 binding to NLGN2 (NL2-Mut3, NL2-Mut5, MDGA1 C8_Mut1, and MDGA1 C8_Mut4 (Lee et al., 2013) , though the molecular basis for its effect on MDGA1 binding was not known. NL2-Mut6 also replaces the equivalent residues as the NLGN1 mutant NL1-5 (Leu 399 Ala/Asn 400 Ala/Asp 402 Asn), which, when expressed on the cell surface, bound the soluble Ig-fusion protein of neurexin 1b, though it had reduced affinity in surface plasmon resonance experiments (K D > 10 mM) (Araç et al., 2007; Ko et al., 2009 , and Asp 377 locate to the binding site for MDGA1 Ig1. To confirm that decreased complex formation was not the result of improperly folded proteins, we also tested binding of the NLGN2 mutants to a fragment of neurexin 1a, n1a L5L6 (which contains the C-terminal domains L5, EGF-C, and L6), and showed that they all bound neurexin about as well as wild-type NLGN2 ( Figure 3F ). Together, the mutational analysis confirms that the interface observed between MDGA1 Ig1-Ig2 and NLGN2 in the crystal structure is physiologically relevant.
To understand how MDGA1 can interfere with the binding of neurexins to NLGN2, we mapped the region of neuroligin that binds neurexin (known from crystal structures of NLGN1 and NLGN4 in complex with neurexin 1b; e.g., Araç et al., 2007; Chen et al., 2008; Fabrichny et al., 2007 ; as well as mutagenesis studies, e.g., Ko et al., 2009 ) onto NLGN2 in the complex with MDGA1 Ig1-Ig2. We also confirmed that neurexin can compete with MDGA1 for NLGN2 binding with purified proteins (Figure S4) . It is clear that Ig1 of MDGA1 shares a binding site on NLGN2 that partially overlaps the region where neurexins bind neuroligins ( Figure 4A ). We conclude that MDGA1 can regulate the formation of trans-synaptic bridges between NLGN2 and neurexins by sterically occluding the neurexin binding site ( Figure 4B) .
A striking selectivity has been observed between MDGAs and neuroligins. MDGA1 binds NLGN2, but not NLGN1 or NLGN3, regulating inhibitory synaptogenesis in vitro and inhibitory synaptic transmission in vivo (Connor et al., 2016; Lee et al., 2013; Pettem et al., 2013) . By contrast, though MDGA2 binds both NLGN1 and NLGN2 in vitro, controlling both excitatory and inhibitory synaptogenesis, in vivo MDGA2 knockdown impacts excitatory, but not inhibitory, synaptic transmission (Connor et al., 2016) . Our studies suggest a structural basis for this selectivity ( Figures 4C and 4D ). MDGA1 Ig1 contacts 21 residues on NLGN2 within 5 Å , but they are virtually conserved between NLGN1, NLGN2, and NLGN3 (except for His 279 ), so they would unlikely encode selectivity ( Figure 4C, top) . However, directly adjacent to His 279 , loop a7-b10 incorporates the large nine-residue site B insert in NLGN1 (in NLGN2 equivalent residues would be Glu 281 -Gly 282 ) ( Figure 4C, top) . This suggests that MDGA1 Ig1 may not be able to accommodate the site B insert, which we could also detect using purified proteins ( Figure 4D ). To accommodate the site B insert, MDGA1 Ig1 loop b5-b6 (which is ordered in the MGDA1 structure, but not in the complex with NLGN2; Figure S5 ) would likely rearrange, acting perhaps as a gatekeeper. However, it is not yet clear why the Ig1 domain from MDGA2 can accommodate site B insert, while that from MDGA1 cannot, given that loop b5-b6 has a similar sequence in MDGA1 and MDGA2. Site A, the other alternative site insert found in neuroligins, located in loop b6-b7 (between Asp   152 and Asp 170 ), is far away from the MDGA1 binding site and unlikely affects the selectivity profile between MDGAs and NLGNs. Ig2 domain of MDGA1 may contribute to the neuroligin selectivity as well because removal of the site B insert in NLGN1 is not sufficient to restore interaction with MDGA1 in cell-surface binding studies (Lee et al., 2013) , though it does rescue binding between purified proteins to some extent ( Figure 4D ). MDGA1 Ig2 contacts 18 residues of NLGN2 within 5 Å , of which 14 are conserved between NLGN1, NLGN2, and NLGN3 and the other four residues are not (Asp (Pettem et al., 2013) . This is supported by the high degree of sequence conservation on the surface of Ig1-Ig2 between the MDGAs ( Figures 4C, bottom, and S2 ). Sixteen residues from Ig1 contact NLGN2 within 5 Å (twelve of which are conserved), and seventeen residues from Ig2 (eleven of which are conserved), while the remaining semi-/non-conserved residues largely segregate to the periphery of the binding site ( Figure 4C, bottom) . The molecular selectivity may result from several semi-conserved substitutions rather than from one particular residue, and additional studies are needed to delve more deeply into the precise mechanism.
DISCUSSION
A new family of synaptic organizers, MDGAs, has emerged that do not possess trans-adhesive function, but rather play a regulatory role by modifying the trans-synaptic adhesion of two other proteins, neurexins and neuroligins. We determined that the first two Ig domains of MDGA1 bind NLGN2 with nanomolar affinity in solution. The MDGA1 Ig1-Ig2 structure shows a rod-shaped array locked by an uncommon interdomain disulfide bond. The structure of the complex between MDGA1 Ig1-Ig2 and NLGN2 reveals two MDGA1 molecules bound to the NLGN2 dimer. Strikingly, each Ig1-Ig2 array spans the entire NLGN2 dimer because Ig1 and Ig2 bind to separate monomers. The binding of MDGA1 Ig1-Ig2 to NLGN2 is mediated by an extensive network of interactions composed of electrostatic interactions, hydrogen bonds, and hydrophobic interactions. Mutagenesis of key residues at the binding interface confirms that the observed interface is physiologically relevant. Ig1 interacts in part with the molecular surface of NLGN2 that is also used by neurexins to bind to neuroligins, thereby revealing the mechanism of regulatory action by MDGAs.
MDGA1 and NLGN2 Subunits
The conformation of MDGA1 Ig1-Ig2 is remarkable because an uncommon interdomain disulfide bond between Ig1 and Ig2 rigidifies the tandem. By holding the two binding surfaces for NLGN2 aligned with respect to each other, the conformational entropy is lowered, which likely increases the binding affinity of MDGA1 Ig1-Ig2 for NLGN2. Strikingly, in the context of fulllength MDGAs, Ig1-Ig2 was predicted to fold back on Ig3-Ig4, adopting a horseshoe-shaped configuration, as seen, for example, in contactins, neurofascin, DCC (deleted in colorectal cancer), and L1 (Chen et al., 2013; Freigang et al., 2000; Liu et al., 2011; Sch€ urmann et al., 2001 ). The horseshoe shape was predicted to require (1) a 5-7 residue linker between Ig2 and Ig3, (2) a W-X-X-N/D motif on the C-C 0 turn in Ig4, and (3) a Gln in the Y-Q-C motif on strand F in Ig4 (Chen et al., 2013) . While MDGA1 meets the first two criteria, the surface of Ig1-Ig2 that is predicted to bury itself against Ig3-Ig4 to form the horseshoe is in fact the interaction site for NLGN2. Therefore, such a horseshoe-shaped arrangement of MDGA1 Ig1-Ig4 would preclude binding to neuroligins. Instead, we show that MDGA1 Ig1-Ig2 and MDGA1 Ig1-Ig4 both bind NLGN2 with nanomolar affinity (Figure 1 ). In fact, we observed that the presence of Ig3 lowered the affinity of MDGA1 fragments toward NLGN2 approximately 10-fold. One explanation is that Ig3 can bend back to interact with Ig2, but that Ig4 has evolved to have a repulsive effect on Ig1, forcing the MDGA1 Ig1-Ig4 array to adopt an extended conformation, thereby promoting efficient interaction with NLGN2.
The MDGA1 Ig1-Ig2 tandem spans the entire NLGN2 dimer, suggesting that MDGA1 might stabilize the NLGN2 dimer. Such stabilization would be important because dimer formation is essential for neuroligin function (Shipman and Nicoll, 2012) . When MDGA1 latches onto NLGN2, the concave surface of MDGA1 Ig2 interacts with the dimerization domain of NLGN2, binding helix a14 and burying helix a13 deeply in its cleft. Helix a13 forms part of an EF-hand motif, a structural feature that had been noted in neuroligins, but for which no function could be assigned yet (Araç et al., 2007) . However, it is known that NLGN2 can also form heterodimers with NLGN3, though their function is not known (Budreck and Scheiffele, 2007; Poulopoulos et al., 2012) , and the residues mediating dimerization are virtually conserved across mammalian neuroligins . Because NLGN3 does not appear to bind to MDGA1 (Lee et al., 2013) , it is therefore possible that the NLGN2:NLGN3 heterodimers bypass regulation by MDGAs because the Ig tandem is not able to bind neuroligin heterodimers efficiently, therefore also suggesting a unique function for them.
MDGA1 Ig1-Ig2:NLGN2 Complex
The MDGA1 and NLGN2 molecules dock together largely as preformed entities in the crystal structure. The Ig1-Ig2 tandem maintains a very similar configuration alone compared to in complex with NLGN2, with the exception of two loops (see Figure S5) ). Second, in Ig2, the loop b12-b13 (in particular Pro 189 -Gln 193 ) moves outward to widen the concave surface of this domain, to accommodate the insertion of NLGN2 helix a13. By contrast, NLGN2 does not appear to undergo any large-scale conformational rearrangements when MDGA1 is bound.
Molecular Mechanism of MDGA1 Regulatory Function
The binding site of neurexin on NLGN1 and NLGN4 was identified by determining several crystals structures, and mutational analyses have confirmed the interaction site (Araç et al., 2007; Chen et al., 2008; Fabrichny et al., 2007; Graf et al., 2006; Ko et al., 2009; Leone et al., 2010; Reissner et al., 2008) . The neuroligin cholinesterase module uses the edge of its central b sheet to bind loops at the rim of the b sandwich and a Ca 2+ -binding site that are located close together in the neurexin LNS domain (L6 in neurexin 1a and the single L domain in neurexin 1b). Electrostatic interactions, hydrogen bonds, a Ca 2+ ion, and a key water molecule comprise the interface, supporting nanomolar affinity between the neuroligins (NLGN1 and NLGN4) and neurexin 1b. While there is significant overlap between the neuroligin residues that bind MDGA1 and those that bind neurexin, the two binding sites do not appear to be identical. Of the 16 NLGN1 residues that bind neurexin within 5 Å , only 11 of these are identical with NLGN2 residues that bind the Ig1 domain of MDGA1 ( Figure S6 ). It is curious that cells expressing NLGN2 and MDGA1, respectively, do not bind each other in co-culture (as assessed by cell aggregation), which would require trans-interaction, while cells expressing neuroligins and neurexins do. The soluble extracellular domain of MDGA1 does bind to cell-surface NLGN2 (Lee et al., 2013) , which suggests that perhaps the manner in which MDGA1 is presented to NLGN2 in the synaptic cleft also plays a role in steering the interactions and limiting binding to cis interactions. In the future, it will be important to more precisely delineate the molecular interactions between neuroligins, MDGAs, neurexins, and the protein networks that they organize in the synaptic cleft because manipulating their interactions selectively could open up new therapeutic avenues to treat their associated neuropsychiatric disorders (Rudenko, 2017) .
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Detailed methods are provided in the online version of this paper and include the following: 
AUTHOR CONTRIBUTIONS
G.R. and S.P.G. conceived the project. X.Z., S.S., H.C., and S.P.G. performed molecular biology, protein purification, and/or crystallization. S.P.G. carried out the binding studies, data collection, and analysis of the structures. G.R. and M.M. carried out the structure determinations. G.R. and S.P.G. wrote the paper. EXPERIMENTAL MODEL AND SUBJECT DETAILS cDNAs used for expression of recombinant proteins were of human, rat and bovine origin. The genes encoding the respective proteins were cloned in the pFastbac vector and expressed using baculovirus mediated overexpression.
METHOD DETAILS Protein Expression and Purification
The extracellular domain of human MDGA1 (NM_153487) with a C-terminal linker and hexa-histidine tag was cloned into the pFastbac vector. ; NM_174404) were made similarly. In addition, a series of mutants were made based on MDGA1 C8 and NLGN2.
The proteins were produced using baculovirus-mediated overexpression in HighFive cells with Insect-XPRESS+L-Glutamine medium (Lonza) at 28
C over an infection course of 70-72 hr. The medium containing the secreted proteins and protease inhibitors (pepstatin, PMSF, leupeptin) was concentrated. For MDGA1 proteins, concentrated media was dialyzed overnight in 25 mM sodium phosphate pH 8.0, 500 mM NaCl, then subjected to Ni-NTA affinity chromatography (Invitrogen), followed by dialysis into 25 mM Tris pH 8.0, 50 mM NaCl and ion-exchange chromatography (Mono S; GE Healthcare) eluting with a NaCl gradient. As a final step, MDGA1 proteins were purified by size exclusion chromatography (HiLoad Superdex-200 16/60; GE Healthcare) in 10 mm HEPES pH 8.0, 50 mM NaCl.
To purify NLGN2, as well as NLGN1 (+/À site B), concentrated media was dialyzed overnight in 20 mM Tris pH 8.0, 500 mM NaCl, then subjected to Ni-NTA affinity chromatography (Invitrogen), followed by dialysis into 20 mM Bis-Tris pH 7.0, 100 mM NaCl and ionexchange chromatography (Mono Q; GE Healthcare) eluting with a NaCl gradient. As a final step, NLGN2 proteins were purified by size exclusion chromatography (HiLoad Superdex-200 16/60; GE Healthcare) in 10 mm HEPES pH 8.0, 150 mM NaCl, while NLGN1 (+/À site B) were purified in 10 mm Tris pH 8.0, 150 mM NaCl. Purified proteins in their gel filtration buffers were concentrated to 10 mg/ml and stored as flash-frozen aliquots at À80 C. Bovine n1a L5L6 was produced as previous described ) also using baculovirus mediated overexpression in HighFive cells. Medium containing the secreted proteins was concentrated, dialyzed in 25 mM sodium phosphate pH 8.0, 500 mM NaCl, and then subjected to Ni-NTA chromatography followed by dialysis in 25 mM Tris pH 8.0, 50 mM NaCl and ion exchange chromatography (Mono Q, GE Healthcare). As a final step, n1a L5L6 was purified by size exclusion chromatography (HiLoad Superdex-200 16/60; GE Healthcare) in 25 mm Tris pH 8.0, 100 mM NaCl.
Protein Labeling MDGA1, the panel of MDGA1 fragments, the panel of MDGA1 C8 mutants and n1a L5L6 were labeled using OneQuant (5/6)-TAMRA-SE fluorescent probe (G-Biosciences). For labeling, 100 mM protein and 1000 mM fluorescent probe, dissolved in 100% DMSO (Sigma), were mixed in 10 mM HEPES pH 7.5 in a reaction volume of 500 mL. The reaction mixture was incubated at room temperature for 2 hr protected from light. The labeled proteins were separated from unbound probe using SpinOUT GT-600 columns (G-Biosciences).
Binding Assay
We developed a fluorescence polarization assay to measure the binding affinity between different TAMRA-labeled proteins and NLGN2. Prior to use, TAMRA (TMR) labeled proteins were diluted in 20 mM HEPES pH 7.5, 25 mM NaCl. A concentration series of 0-500 nM NLGN2 with a fixed concentration of 30 nM TMR-labeled protein in 20 mM HEPES pH 7.5, 25 mM NaCl was made in 96-well flat bottom black assay plates (Corning-3991) using 200 ml/well. To measure the interaction of TMR-MDGA1 C8 with NLGN2, NLGN1(+ site B) and NLGN1(-site B), concentration series containing 0 -125 nM neuroligins were made in 20 mM HEPES pH 7.5, 75 mM NaCl with 30 nM TMR-labeled protein added. After incubation at room temperature for 15-20 min, fluorescence polarization was measured using a Pherastar plate reader (BMG Labs) at 25 C, with excitation at 540 nm, emission at 590 nm, 100 flashes per well, and the target set to 50 mP for the TMR-labeled tracer by adjusting the gain on a well with 30 nM TAMRA in H 2 O. Data were processed using Prism 6.0 (GraphPad Software), fitting the binding curves to a 'One Site-Total Binding' model. Each data point represents the mean of triplicates, and the error bar represents the standard deviation. The fluorescence polarization observed for 30 nM TMR-labeled tracer alone was set as the baseline value and subtracted from the values measured for 30 nM TMRtracer in the presence of increasing amounts of NLGN2.
Competitive Binding Assay
To measure the competition of MDGA1 and neurexin for NLGN2 a modified FP-assay was used. First, the MDGA1 Ig1-Ig2:NLGN2 complex was made by mixing 5 nM TMR-MDGA1 C8 and 100 nM NLGN2 in 10 mM HEPES pH 7.5, 50 mM NaCl, 1 mM CaCl 2 and 0.01% Triton X-100. Subsequently, the complex and n1a L5L6 was dispensed in a 96-well flat bottom black assay plate (Corning-3991) so that each well received a final volume of 100 ml complex containing a serial dilution of n1a L5L6; separately wells with TMR-MDGA1 C8:NLGN2 but no n1a L5L6 were also taken along to form a final concentration range of 0 -4000 nM n1a L5L6. Plates were incubated at room temperature for 1 hr with gentle shaking; then the fluorescence polarization was measured using a Pherastar plate reader (BMG Labs) at 25 C, with excitation at 540 nm, emission at 590 nm, 200 flashes per well, and the target set to 50 mP for the TMR-labeled tracer by adjusting the gain on a well with 5 nM TAMRA in H 2 O. Data were processed as above. Each data point represents the mean of duplicates, and the error bar represents the standard deviation.
Crystallization
Crystals of MDGA1 C8 (Ig1-Ig2) were grown at 20 C by mixing 2.5 ml of protein at 1.5 mg/ml and 2.5 ml of reservoir solution (1.5 M ammonium sulfate, 3.72% (v/v) 2-propanol, 25% (v/v) glycerol) in a hanging drop setup. Crystals were harvested directly from the crystallization drops and flash cooled. The crystals exhibit the symmetry of space group I23 with unit cell dimensions a = b = c = 139.07 Å , a = b = g = 90 and diffract to 2.76 Å . To grow crystals of the MDGA1 Ig1-Ig2:NLGN2 complex, the two proteins were mixed (NLGN2 at $3.9 mg/ml and MDGA1 C8 at $2.4 mg/ml, respectively, to achieve a ratio of 60:90 mM) in 10 mM HEPES pH 8.0, 50 mM NaCl and incubated at room temperature for $1 hr. Crystals were obtained at 20 C by mixing 2.5 ml of protein complex and 2.5 ml of reservoir solution ( , b = 80.97 , g = 88.71 and diffract to 4.1 Å . Diffraction datasets were collected at the Advanced Photon Source (LS-CAT, SBC-CAT and IMCA-CAT). Data were processed with HKL2000 (Otwinowski and Minor, 1997) and data statistics are given in Table 1 .
Structure Determination of MDGA1 Ig1-Ig2
The structure of MDGA1 Ig1-Ig2 was determined by molecular replacement using the program MrBUMP (Keegan and Winn, 2008) using the coordinates of the insect immune protein hemolin (PDB: 1BIH; Su et al., 1998) as search model. Model building was iteratively carried out with the program Coot (Emsley et al., 2010 ) interspersed with refinement using the Phenix program package (Adams et al., 2010) . The refined model consists of 198 residues (Tyr 22 -Thr mouse, AAI50774.1), MDGA1 (human, NM_153487.3; bovine, NP_001179811.1; rat, NP_001101088.1; mouse, ABG78614.1) and MDGA2 (human, NP_001106970.3; bovine, XP_015320545.1; rat, NP_954890.1; mouse, AAI37903.1). The following groups of residues were considered semi-conserved (I, V, L, M); (F, Y, W); (K, R, H), (D, E, N, Q); (G, A, S, T); (C) and (P). Figures were prepared using the PyMol Molecular Graphics System, Schrö dinger.
QUANTIFICATION AND STATISTICAL ANALYSIS
Fluorescence polarization data was processed using Prism 6.0 (GraphPad Software). For fluorescence polarization experiments, values are shown as mean ± standard deviation (described in Method Details).
DATA AND SOFTWARE AVAILABILITY
The coordinates for MDGA1 Ig1-Ig2 and MDGA1 Ig1-Ig2:NLGN2 complex reported in this paper have been deposited in the Protein Data Bank under accession numbers PDB: 5V5W and 5V5V, respectively.
